Latest Conference Articles

Five-year KEYNOTE-942 data show intismeran plus pembrolizumab delivers durable improvements in RFS and DMFS in high-risk resected melanoma.

“In this interim analysis…the response rate with the zelenectide pevedotin and pembrolizumab [was] promising, supporting its benefit-risk profile and supporting…the optimized dosing," said Yohann Loriot, MD, PhD.

Dr McDonald shares promising data linking GLP-1 use to lower breast cancer risk, highlighting the need for clinical trials to prove prevention.

ctDNA clearance and baseline detectability emerge as prognostic markers in the StrateGIST 1 trial; favorable ORRs seen in early-line cohorts.

"Dedifferentiated liposarcoma is usually treated with surgery, but when it comes back, it is difficult to treat and often incurable," said Mark Dickson, MD.

"These findings may be considered practice changing for medical oncologists treating HCC globally,” said Vishwanath Sathyanarayanan, MD.

The IGNYTE continues to show promising outcomes despite negative FDA decisions.

Andrew J. Wagner, MD, PhD reviews phase 3 PEAK data on bezuclastinib plus sunitinib in advanced GIST at ASCO 2026.

Roberto Mina, MD, discusses takeaways from the MajesTEC-9 trial results at ASCO.

Daniel Olson, MD, discusses the results of a phase 1 trial of brenetasfusp, a PRAME ImmTAC therapy in advanced melanoma.

The AKT inhibitor ipatasertib resulted in 41% overall response rate when combined with pembrolizumab in head and neck squamous cell carcinoma.

"Early molecular testing is critically important now in these [patients with] mCSPC,” said TALAPRO-3 lead investigator Neeraj Agarwal, MD, FASCO.

"I think the [PROTEUS] study will change the standard of care for many patients who are candidates for surgery and have high-risk localized prostate cancer,” said William K. Oh, MD.

“The results support daraxonrasib as the new standard of care for patients with previously treated metastatic PDAC,” said Brian Wolpin, MD.

"Adjuvant selpercatinib should be considered as a new standard of care in early-stage RET fusion–positive lung cancer,” said Jonathan Goldman, MD.

“This study is important in that it represents a potential therapy option for patients in resource-limited parts of the world," said Glenn J. Hanna, MD.

The bezuclastinib/sunitinib combo is being reviewed by the FDA for approval in GIST based on the PEAK study findings.

SENOMAC at ASCO 2026 shows skipping completion ALND in select breast cancer keeps survival high and cuts lymphedema, boosting quality of life.

Prior RAMPART results had shown durvalumab plus tremelimumab significantly improved DFS in resected renal cell carcinoma.

“MajesTEC-9 is the second phase 3 study to show a significant PFS and OS benefit in the second-line setting and beyond with teclistamab-based therapy for RRMM,” said Roberto Mina, MD.

Discover the final 7.8-year survival data from KEYNOTE-522 and see how adding pembrolizumab to chemotherapy drastically cuts recurrence for early TNBC.

“We believe that the combination of [Tafa-Len-R-CHOP] is a potential new standard for frontline therapy for patients with intermediate or high-risk [DLBCL] or [HGBL],” said Georg Lenz, MD.

SUCCESSOR-2 shows oral mezigdomide plus carfilzomib/dexamethasone extends PFS to 18 months in high-risk relapsed myeloma.

"The key finding is that more axillary surgery in itself does not improve survival in these patients," said Jana de Boniface, MD, PhD.

“Further investigation of intravesical rBCG in combination with next-generation systemic regimens in randomized trials is warranted,” said Richard Cathomas, MD.

Notably, patients in EV-302 who converted from PR to CR achieved survival outcomes similar to those who achieved CR directly.

Belantamab plus VRd in newly diagnosed myeloma yields response rates over 85% with dose schedules to manage ocular toxicity.

ROSELLA update shows consistent OS benefit with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, irrespective of prior taxane use.

Long-term RUBY data show dostarlimab plus chemo drives durable remission and potential cure in many patients with dMMR/MSI-H advanced or recurrent endometrial cancer.

"This [TALAPRO-2] analysis represents the first...patient-level analysis to evaluate rPFS–OS correlation for a PARP inhibitor in first-line mCRPC," said Neeraj Agarwal, MD.